CSL projects 10-13% NPATA growth for fiscal 2025 amid strong Behring performance and Seqirus recovery plans
CEO McKenzie stated that CSL's differentiation strategy and focus on innovation will support the company's position. Analysts ...
Mirage News5d
PolyNovo Announces Chief Executive Change
PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but ...
Capital Brief6d
PolyNovo CEO Swami Raote to step down immediately
Medical devices manufacturer PolyNovo has announced that its chief executive Swami Raote will step down from his role ...
The Business Journals21d
Pfizer shelves Beqvez, a Spark Therapeutics developed product
In a conference call with investment analysts last year, CSL CEO Paul McKenzie said sales of Hemgenix have progressed slower than expected. "We had 12 [patients on the therapy] in 2024," McKenzie ...
Esperion partners with CSL Seqirus to commercialize NEXLETOL, NEXLIZET
Therapeutics announced it has entered into a license and distribution agreement with CSL Seqirus for the exclusive rights to ...
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL ® (bempedoic ...